Vitamin B3 study explores how body handles supplement during illness
NCT ID NCT07156929
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed study looked at how a special form of vitamin B3 (nicotinamide) is processed in 28 patients with low tryptophan levels due to respiratory infections or inflammatory bowel disease. Participants took either 500 mg or 1000 mg of the supplement daily for four weeks. The main goal was to measure changes in vitamin B3 and related substances in the blood, not to test if it treats the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
controlled-ileocolonic-release nicotinamide (a special form of vitamin B3)
What this could lead to
If successful, this could help design better vitamin B3 supplements for people with low tryptophan levels due to infections or chronic inflammation.
What could go wrong
This is a small, early study with only 28 participants and no control group. It mainly measures how the body processes the supplement, not whether it improves health outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Schleswig-Holstein, Campus Kiel
Kiel, Schleswig-Holstein, 24105, Germany